The present invention is directed to combinations of a β-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of β-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.

##STR00001##

The present invention is directed to combinations of a β-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of β-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.

##STR00001##

The present disclosure provides compositions and methods for treating Clostridium difficile infection (CDI) including primary and recurrent CDI. In particular, the compositions and methods described herein are capable of achieving a CDI clearance rate of at least 80% through a single oral dose of a pharmaceutical composition comprising a freeze-dried fecal microbiota preparation.

The present invention relates to a method for selecting an immunomodulatory kit, selected for an individual patient, for use in the treatment of patients suffering from myeloid leukemias. Different kits are available for selection and ex vivo testing which are composed of substances that have different immunomodulatory effects on leukemia cells. Each kit particularly contains GM-CSF and one (or two) more substances, selected from PICIBANIL, PGE.sub.1, PGE.sub.2, CALCIMYCIN and TNFα, as well as pharmaceutically acceptable adjuvants. The clinical aim is to modify, once the individually selected immunomodulatory kits were administered, blast cells in the body of the patient such that they turn into a “vaccine” which is able to activate the immunoreactive cells (of the patient or of the stem cell donor) in the body against blast cells.

The present invention relates to a method for selecting an immunomodulatory kit, selected for an individual patient, for use in the treatment of patients suffering from myeloid leukemias. Different kits are available for selection and ex vivo testing which are composed of substances that have different immunomodulatory effects on leukemia cells. Each kit particularly contains GM-CSF and one (or two) more substances, selected from PICIBANIL, PGE.sub.1, PGE.sub.2, CALCIMYCIN and TNFα, as well as pharmaceutically acceptable adjuvants. The clinical aim is to modify, once the individually selected immunomodulatory kits were administered, blast cells in the body of the patient such that they turn into a “vaccine” which is able to activate the immunoreactive cells (of the patient or of the stem cell donor) in the body against blast cells.

Disclosed herein are methods and compositions that can be used to improve motor deficits and neuroinflammation in subjects in need, for example subjects suffering from neurodegenerative disorders (e.g., Parkinson's disease). Also disclosed are methods and compositions that can be used to diagnose neurodegenerative disorders, such as Parkinson's disease.

Provided is an anti-tumor composition, comprising: (A) Akkermansia muciniphila; and (B) an immune checkpoint inhibitor, such as a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, etc. Also provided is use of Akkermansia muciniphila in preparing a drug for treating tumor.

Provided is an anti-tumor composition, comprising: (A) Akkermansia muciniphila; and (B) an immune checkpoint inhibitor, such as a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, etc. Also provided is use of Akkermansia muciniphila in preparing a drug for treating tumor.

A hydrate promoter contains a component A which is a substance having a group represented by the Formula I below and a surfactant. A molar ratio of the component A to the surfactant is 1:(0.03-30). The hydrate overcomes the disadvantages of the conventional hydrate promoter, such as small gas storage capacity and low generation rate, the present disclosure is further capable of suppressing generation of air bubbles and improving the gas recovery rate of hydrate during decomposition process of the hydrate, as compared to the conventional hydrate promoter, thus has a favorable application prospect for natural gas storage and transportation with the hydrate.

##STR00001##

A hydrate promoter contains a component A which is a substance having a group represented by the Formula I below and a surfactant. A molar ratio of the component A to the surfactant is 1:(0.03-30). The hydrate overcomes the disadvantages of the conventional hydrate promoter, such as small gas storage capacity and low generation rate, the present disclosure is further capable of suppressing generation of air bubbles and improving the gas recovery rate of hydrate during decomposition process of the hydrate, as compared to the conventional hydrate promoter, thus has a favorable application prospect for natural gas storage and transportation with the hydrate.

##STR00001##